Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates

Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns

(2014) Xingwang Zhang et al.   Expert Opinion on Drug Metabolism & Toxicology

PEGylation and its impact on the design of new protein-based medicines

(2014) Claire Ginn et al.   Future Medicinal Chemistry

The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule

(2014) L. A. Valentino et al.   HAEMOPHILIA

New challenges and opportunities in nonclinical safety testing of biologics

(2014) Andreas Baumann et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models

(2013) H. R. Stennicke et al.   BLOOD

Current challenges and opportunities in nonclinical safety testing of biologics

(2013) Sven Kronenberg et al.   DRUG DISCOVERY TODAY

High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to Proteins

(2013) Daniel G. Rudmann et al.   TOXICOLOGIC PATHOLOGY

PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers

(2012) I. A. Ivens et al.   HAEMOPHILIA

PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery

(2011) Paola Milla et al.   CURRENT DRUG METABOLISM

PEGylation of therapeutic proteins

(2010) Simona Jevševar et al.   Biotechnology Journal

Peptide and protein PEGylation III: advances in chemistry and clinical applications

(2007) Francesco M. Veronese et al.   ADVANCED DRUG DELIVERY REVIEWS